Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Morphosys AG Increases FY 2013 Guidance
Morphosys AG announced that it has increased its financial guidance for full fiscal year 2013, and expects an EBIT of EUR 7 million to EUR 10 million (up from previously EUR 2 million to EUR 6 million) and revenues at the upper end of the previously communicated guidance range of EUR 74 million to EUR 78 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2013 EBIT of EUR 7.12 million and revenue of EUR 72.87 million.
Latest Developments for Morphosys AG
Latest Key Developments in Biotechnology
- Auspex announces pricing of follow on offering
- Serendex Pharmaceuticals starts trading on Oslo Axess
- Biotie Therapies Oyj decides not to exercise option to acquire Neurelis Inc but retains economic interest in future success of NRL-1
- KYTHERA Biopharmaceuticals announces FDA acceptance of ATX-101 New Drug Application
- Share this
- Digg this